Nijhawan Pardeep 4

What Happened Pardeep Nijhawan, CEO of Edesa Biotech (EDSA), was granted 1,159 restricted share units (RSUs) on May 1, 2026. The filing reports these as an award/acquisition (code A) at a reported price of $0.00. Per the filing, the RSUs vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan (footnote F1).

Key Details

• Transaction date: 2026-05-01; transaction type: Award/Grant (code A).
• Shares involved: 1,159 RSUs; reported acquisition price: $0.00.
• Vesting: RSUs vested in full upon grant (see F1).
• Beneficial ownership notes: Several entities (Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc., 1968160 Ontario Inc.) are wholly owned by the reporting person; he disclaims beneficial ownership of those securities except to the extent of pecuniary interest (F2). He is also co-trustee of The New Nijhawan Family Trust 2015 and similarly disclaims beneficial ownership except to extent of pecuniary interest (F3).
• Shares owned after transaction: Not specified in the provided excerpt.
• Filing timeliness: Reported and filed on 2026-05-01 (same-day filing per the accession info).

Context This was a compensation-related grant of RSUs that vested immediately and converted to shares (no cash paid at grant, hence $0 reported). Such awards are standard executive compensation and do not, by themselves, indicate a buy or sell decision by the insider. The footnotes clarify ownership structure and that the reporting person disclaims beneficial ownership of certain shares except for his pecuniary interest.